How it works:
Afatinib is an irreversible tyrosine kinase inhibitor that targets members of the ErbB family, including EGFR (ErbB1), HER2, and HER4. By blocking intracellular signalling pathways that promote tumour cell proliferation and survival, afatinib delays disease progression. It is particularly effective in patients with common EGFR mutations such as exon 19 deletions and the L858R point mutation in exon 21.
Recommended For:
Patients diagnosed with EGFR mutation-positive non-small cell lung cancer
First-line treatment in locally advanced or metastatic stages
Those ineligible for chemotherapy or preferring oral targeted therapy
Under oncologist supervision with genetic confirmation of EGFR mutations
First-line treatment of EGFR mutation-positive NSCLC
Locally advanced or metastatic NSCLC
Adults with confirmed EGFR-activating mutations
AFANAT 40mg is taken orally once daily, preferably on an empty stomach. The standard dose is 40mg per day, but dose adjustments may be required based on tolerance and side effects, as advised by the treating physician.
Contraindications:
Hypersensitivity to afatinib or its components
Severe hepatic or renal impairment
Pregnancy and breastfeeding
Paediatric patients
Side Effects:
Diarrhoea, nausea
Skin rash, dryness, dermatitis
Stomatitis
Elevated liver enzymes
Loss of appetite, weight loss
Rare: Interstitial lung disease
